Cutaneous T-Cell Lymphoma (CTCL) Completed Phase 2 Trials for Quisinostat (DB12985)

Also known as: Cutaneous T Cell Lymphoma (CTCL) / Cutaneous T Cell Lymphomas (CTCL) / Cutaneous T-Cell Lymphoma / Cutaneous T Cell Lymphoma / Cutaneous T-Cell Lymphomas / CTCL / Primary cutaneous T-cell lymphoma (morphologic abnormality) / Cutaneous T-cell lymphoma (morphologic abnormality) / Primary cutaneous T-cell lymphoma (disorder) / Lymphoma, T-Cell, Cutaneous

DBCOND0071861 (Cutaneous T-Cell Lymphoma (CTCL))Completed2 IdentifierTitlePurposeDrugs
NCT01486277A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell LymphomaTreatment